Eco Animal Health Group PLC Animal Health Innovation Summit

TIDMEAH

Eco Animal Health Group PLC

08 March 2023

ECO Animal Health Group plc

("ECO" or "the Group ")

(AIM: EAH)

Animal Health, Nutrition & Technology Innovation

ECO Animal Health Group plc ("ECO" or "the Group"), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that it will be participating at the Animal Health, Nutrition and Technology Innovation summit and leading the round table discussion on swine disease management.

Animal Health, Nutrition and Technology Innovation Europe is the sector's premier innovation summit, showcasing the emerging companies and connecting them with investors and strategic partners. The summit engages all key participants in the value chain so it can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.

Please find further information on the event at https://kisacoresearch.com/events/animal-health-europe-2023

Contacts:

 
 ECO Animal Health Group plc 
  David Hallas (CEO) 
  Christopher Wilks (CFO)                      020 8447 8899 
 IFC Advisory 
  Graham Herring 
  Zach Cohen                                  020 3934 6630 
 Singer Capital Markets (Nominated Adviser 
  & Joint Broker) 
  Phil Davies 
  George Tzimas                               020 7496 3000 
 Investec (Joint Broker) 
  Gary Clarence 
  Daniel Adams 
  Carlo Spingardi                             020 7597 5970 
 Equity Development 
  Hannah Crowe 
  Matt Evans                                  020 7065 2692 
 

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUBRVROUUORAR

(END) Dow Jones Newswires

March 08, 2023 02:00 ET (07:00 GMT)